Antiviral Resistance against Viral Mutation: Praxis and Policy for SARS-CoV-2
Tools developed by Moderna, BioNTech/Pfizer, and Oxford/Astrazeneca, among others, provide universal solutions to previously problematic aspects of drug or vaccine delivery, uptake and toxicity, portending new tools across the medical sciences. A novel method is presented based on estimating protein...
Guardado en:
Autor principal: | |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
De Gruyter
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d8f1b8f6200c425c8f397dbbc6e2091b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sea el primero en dejar un comentario!